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Abstract
Background: Patients with acute mania respond differentially to treatment and, in many cases, fail
to obtain or sustain symptom remission. The objective of this exploratory analysis was to
characterize response in bipolar disorder by identifying groups of patients with similar manic
symptom response profiles.
Methods: Patients (n = 222) were selected from a randomized, double-blind study of treatment
with olanzapine or divalproex in bipolar I disorder, manic or mixed episode, with or without
psychotic features. Hierarchical clustering based on Ward's distance was used to identify groups of
patients based on Young-Mania Rating Scale (YMRS) total scores at each of 5 assessments over 7
weeks. Logistic regression was used to identify baseline predictors for clusters of interest.
Results: Four distinct clusters of patients were identified: Cluster 1 (n = 64): patients did not
maintain a response (YMRS total scores ≤ 12); Cluster 2 (n = 92): patients responded rapidly
(within less than a week) and response was maintained; Cluster 3 (n = 36): patients responded
rapidly but relapsed soon afterwards (YMRS ≥ 15); Cluster 4 (n = 30): patients responded slowly
(≥ 2 weeks) and response was maintained. Predictive models using baseline variables found YMRS
Item 10 (Appearance), and psychosis to be significant predictors for Clusters 1 and 4 vs. Clusters
2 and 3, but none of the baseline characteristics allowed discriminating between Clusters 1 vs. 4.
Experiencing a mixed episode at baseline predicted membership in Clusters 2 and 3 vs. Clusters 1
and 4. Treatment with divalproex, larger number of previous manic episodes, lack of disruptive-
aggressive behavior, and more prominent depressive symptoms at baseline were predictors for
Cluster 3 vs. 2.
Conclusion: Distinct treatment response profiles can be predicted by clinical features at baseline.
The presence of these features as potential risk factors for relapse in patients who have responded
to treatment should be considered prior to discharge.
Trial registration: The clinical trial cited in this report has not been registered because it was
conducted and completed prior to the inception of clinical trial registries.
Background
Manic episodes in bipolar disorder requiring hospitaliza-
tion contribute to substantial personal and economic bur-
den on patients, their families and society [1], which
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could be alleviated with rapid resolution of acute manic
symptoms [2]. Unfortunately, patients with acute mania
can respond differentially to treatment due to underlying
symptomatic dimensions that vary individually, which
can result in failure to obtain or sustain symptom remis-
sion [3]. Behavioral subtypes in mania have been
described [4] and were found to respond differently to
treatment [3] even though the pattern of manic symptom
reduction in response to treatment was not found to dif-
fer. However, this observation was based on endpoint
measures, and any treatment-associated differences in the
pattern of symptom change that occurred earlier during
treatment may have been missed [3]. What might be of
potential utility to the clinician would be to identify dis-
tinct time-course patterns of acute treatment response.
The objective of the present study was to identify groups
of patients with similar response profiles and to construct
predictive models for these groups using baseline data.
The present study is unique in that patients with acute
mania were assessed daily during the first week of treat-
ment which allowed the capture of symptom changes that
characterized their longer-term response to treatment.
Methods
Study design and patient population
This was a post-hoc analysis of patients (n = 222) with
bipolar mania or mixed-episode, with or without psy-
chotic features, from a randomized, double-blind clinical
trial comparing olanzapine (n = 125; 5–20 mg/d) and
divalproex (n = 123; 500–2500 mg/d) in a 3-week acute
phase [5] followed by a 44-week maintenance phase [6].
Details of this study have been reported elsewhere, and
the following is a brief summary. Acute mania was
assessed as having Young-Mania Rating Scale (YMRS) [7]
total scores ≥ 20 at baseline. Depressive symptoms were
assessed with the Hamilton Rating Scale for Depression
(HAMD) [8]. Patients were assessed daily during the first
week, weekly for the following 2 weeks, and then bi-
weekly for the remainder of the study (a total of 7 weeks
for this analysis).
During this study period, remission was defined as having
YMRS total scores ≤ 12, and sustained remission was
defined as having YMRS total scores ≤ 12 for at least 2 sub-
sequent visits including the last one (discontinuation or at
Week 7, whichever occurred first). Relapse (ongoing
mania or recurring mania post-baseline after treatment
initiation) was defined as having YMRS total scores ≥ 15
at any assessment, and "sustained relapse" (sustained
manic episode) was defined as having YMRS total scores ≥
15 for at least 2 subsequent visits including the last one
(discontinuation or at Week 7, whichever occurred first).
To facilitate clinical interpretation of the resulting clusters,
sustained remission and sustained relapse were evaluated
as binary outcomes for each cluster.
Statistical methods
The objective of the present analysis was to identify dis-
tinct response-to-treatment profiles in acute mania that
may be representative of certain types of patients, their
disease history, baseline conditions, or treatment regi-
men. An easy-to-implement way of identifying different
patterns of treatment response is by clustering estimated
regression coefficients fitted to each individual patient's
response profile [9-11]. To achieve this, a method of hier-
archical clustering based on Ward's distance was applied
to the estimated coefficients of orthogonal polynomial
regressions of the third degree that were fitted to YMRS
total scores during the first 7 weeks of treatment. To
smooth YMRS profiles, splines were applied to the data
(prior to fitting orthogonal polynomials) using penalized
least-squares estimates from a non-parametric regression
(SAS® PROC TPSPLINE). This procedure adapts to the pat-
tern of individual profiles by varying model complexity
for individual curves. While attempting to reach good fit
to the data, this procedure also avoids excessive roughness
or rapid variation [12,13]. The outlined procedure of
approximating data using orthogonal basis functions
(here polynomials) and clustering estimated coefficients
appears quite naturally in the context of functional data
analysis [9-11,14]. Specifically, when using orthogonal
polynomials, the coefficients have the following natural
interpretation, independently of other terms included: the
coefficient at linear term represents an overall trend in the
outcome profile, the coefficient at quadratic term is the
rate of change in the expected outcome at time t, and so
on [11].
The number of clusters that best represented patient
response to treatment as revealed by hierarchical cluster-
ing was selected by comparing the percent variation
accounted for by the clusters (R2) achieved at each level of
data aggregation. The level(s) that corresponded to subse-
quent sharp deterioration of R2 were selected for further
inspection, and the clusters that were the most interpreta-
ble in terms of clinical relevance were selected for final
presentation.
One difficulty encountered with this dataset was the large
number of patient dropouts. In order to regularize the
data prior to fitting the curves, profiles of patients who
discontinued during Weeks 2–7 of treatment were com-
pleted using the average of 50 imputed values generated
with Bayesian regression fitted to the previous outcomes
at every time point past the first week (SAS® PROC MI).
This imputation procedure is consistent with the likeli-
hood of observed data and is not expected to introduce
any bias when evaluating representative curve shapes, asBMC Psychiatry 2008, 8:65 http://www.biomedcentral.com/1471-244X/8/65
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long as data are missing at random (that is, the probability
of dropouts does not depend on unobserved outcomes
after the observed outcomes have been accounted for).
To identify baseline variables that may have been contrib-
uting to membership in a particular cluster, logistic regres-
sion (SAS®  PROC LOGISTIC) with stepwise variable
selection was used. Baseline variables included in the
analysis were: HAMD total scores, individual YMRS items
scores, gender, ethnicity, age, weight, body mass index
(BMI), index episode and/or illness features (mixed, psy-
chotic, rapid cycling), number of previous manic, mixed,
or depressive episodes in the previous year/or lifetime,
number of hospitalizations, age at onset of illness, and
treatment during the study (olanzapine vs. divalproex).
Results
Baseline characteristics of patients included in this analy-
sis are summarized in Table 1. Patients were mostly white,
in their forties; nearly half were experiencing a mixed-epi-
sode and/or had psychotic features. The average number
of manic episodes in the previous year was about 4.
Four clusters were identified that best represented patient
response to treatment. This identification was based upon
comparing the proportion of variation (R2) accounted for
by joining the 2 closest clusters when trying to reduce the
number of clusters that resulted from the analysis. R2
started deteriorating substantially at levels corresponding
to solutions with 5 to 4 clusters. The solution with 5 clus-
ters did not introduce substantially different patterns,
whereas 4 clusters seemed to capture distinct mania
course profiles as shown in Figure 1.
In order to provide a visual assessment of the distinctness
of the clusters, individual mania profiles (YMRS total
scores) of the patients within each cluster were plotted
(Figure 2A–D). To facilitate clinical interpretation of the
clusters, the individual responses were characterized in
terms of 2 binary outcomes: sustained remission and sus-
tained relapse. This was implemented by assigning differ-
ent colors to illustrate when a patient achieved a particular
outcome. More specifically, the color magenta was used to
represent when sustained relapse criterion was first met
(YMRS total ≥ 15) by the patient, and this color was con-
tinued for all subsequent time points until Week 7 or dis-
continuation. Sustained remission (YMRS total ≤ 12) was
represented by the color green starting with when the cri-
terion was first met by the patient, and this color was con-
tinued for all subsequent time points until Week 7 or
discontinuation. Light blue was used for all time points
when neither criterion was met by the patient. Inspecting
the multicolored raw curves within their respective clus-
ters provides reassurance that the clusters were not simple
artifacts induced by various data transformations (impu-
tation of missing data, smoothing and fitting regressions)
and the clustering algorithm itself.
Cluster 1 (Figure 2A) included patients (n = 64) most of
whom (95%) did not attain sustained remission of manic
symptoms, and who largely (over 50% of them) had a sus-
tained relapse. In this cluster, mania symptoms gradually
improved during the first week (mean YMRS total scores
= 19.6 [SD 8.8] at Day 7), and 46% of the patients were
discharged from the hospital by the end of the first week.
In the following weeks, mania symptoms of patients in
Cluster 1 improved slightly, but by the end of Week 7
most of these patients still had not remitted indicating
poor response to treatment.
Cluster 2 (Figure 2B) included patients (n = 92) who expe-
rienced rapid improvement in their symptoms in the first
2 days, and by Day 7, mean YMRS total score was 10.2
(5.8), and 86% were discharged. Most of the patients in
this cluster (66%) reached a sustained remission and con-
tinued to improve for the duration of the study, and only
5% had a sustained relapse.
Cluster 3 (Figure 2C) included patients (n = 36), who also
experience rapid improvement in their symptoms within
Table 1: Baseline characteristics of patients who had at least one week of active treatment.
Olanzapine 
(n = 111)
Divalproex 
(n = 111)
YMRS total, mean (SD) 27.3 (5.0) 27.8 (6.7)
HAMD-21 total, mean (SD) 15.1 (7.5) 13.4 (6.9)
Gender (% male) 42.3 41.4
Age, year, mean (SD) 40.15 (12.2) 42.3 (11.8)
Ethnicity (% white) 77.5 84.7
Weight, kg, mean (SD) 80.4 (20.5) 79.2 (20.9)
Mixed episode (%) 47.7 39.6
Psychotic features (%) 49.5 39.6
Rapid cycling (%) 61.3 52.3
Number of manic episodes in previous year, mean (SD) 4.8 (7.3) 3.6 (6.2)BMC Psychiatry 2008, 8:65 http://www.biomedcentral.com/1471-244X/8/65
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the first 2 days of treatment, but their symptoms had
worsened slightly by Day 7, even so 84% were discharged
during the initial week of treatment. Most (82%) of the
patients in Cluster 3 had met relapse criterion at Week 2
(n = 34, mean YMRS total score of 21.8 [8.4]), and their
YMRS scores did not improve substantially thereafter:
72% of them had maintained relapse until the end of the
7-week period (or discontinuation). There was only one
patient (3%) in this cluster who had a sustained remis-
sion.
Cluster 4 (Figure 2D) included patients (n = 30) whose
mania symptoms improved gradually during the first
week and 66% were discharged. Most (83%) of the
patients in this cluster were remitted by Week 2, and 80%
maintained their remission for the duration of the 7-week
period (or until discontinuation). There was only one
patient (3%) who had a sustained relapse.
The characteristics of the patients within each cluster prior
to initiation of treatment are summarized in Table 2.
Patients in Clusters 1 and 4 shared similar clinical charac-
teristics at baseline even though they had different
response profiles past Week 1 (Figure 1). Patients in both
Clusters 1 and 4 tended to have psychotic features, fewer
manic episodes in the preceding year, and over 50%
received divalproex; they had also similar baseline HAMD
mean total scores, which were slightly higher for patients
in Cluster 1 (13.6 [7.7] vs. 11.5 [6.2], p = ns). Membership
in Clusters 1 and 4 vs. 2 and 3 was predicted by baseline
YMRS Item 10 (Appearance) (adjusted OR = 1.77, 95%
CI: 1.24–2.53, p = .002), psychotic features (adjusted OR
Response profiles of clusters Figure 1
Response profiles of clusters. Cluster 1, slow responders who subsequently relapsed. Cluster 2, early symptom improve-
ment in patients who achieved sustained remission. Cluster 3, early symptom improvement in patients who subsequently 
relapsed. Cluster 4, slow responders who subsequently remitted. The horizontal solid line represents the threshold for relapse 
(YMRS total score of 15), and the horizontal dashed line represents the threshold for remission (YMRS total score of 12).
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= 6.54, 95% CI: 3.28–13.08, p < .001), and by not being
in a mixed index episode at baseline (adjusted OR = 0.19,
CI: 0.10–0.39, p < .001). Membership in Clusters 1 and 4
vs. Clusters 2 and 3 was not predicted by randomization
to either treatment. None of the baseline characteristics,
however, allowed discriminating between membership in
Cluster 1 vs. 4.
Patients in Clusters 2 and 3 also shared certain clinical
characteristics at baseline, but had different outcomes
(Figure 1): less than one-third of the patients in these clus-
ters had psychotic symptoms, over 50% were in a mixed
episode, and over 60% were rapid cycling. Cluster 3
patients were poor responders with an average of 8 manic
episodes in the year preceding study entry, and over two-
thirds were randomized to divalproex. Cluster 2 patients,
who were responders, had on average 4 manic episodes in
the preceding year and over 60% were randomized to
olanzapine. Membership in Cluster 3 vs. 2 was signifi-
cantly predicted by randomization to divalproex
(adjusted OR = 5.0, CI: 1.88–13.3, p = .001), experiencing
a larger number of manic episodes over the previous 12
months (adjusted OR = 1.11, 95% CI: 1.04–1.18, p =
.001), lack of disruptive-aggressive behavior (YMRS Item
Clusters with individual patient response profiles Figure 2
Clusters with individual patient response profiles. Individual patient response profiles within each cluster. Colors within 
each profile were assigned as follows: "magenta" for all time points starting when sustained relapse criterion was first met 
(YMRS total ≥ 15) until week 7 or discontinuation; "green" for all time points starting when sustained remission criterion was 
first met (YMRS total ≤ 12) until week 7 or discontinuation; "light blue" for all the time points when neither sustained relapse 
nor remission criterion were met. Horizontal lines indicate the cut-offs for relapse (red) and remission (black). The dark blue 
line represents the mean response. A. Cluster 1 patients (n = 64) showing slower response, most of whom had a sustained 
relapse (magenta lines) or did not meet relapse or remission criteria (blue lines). B. Cluster 2 patients (n = 92) showing rapid 
early improvement, and most of them had a sustained remission (green lines). C. Cluster 3 patients (n = 36) showing rapid 
early improvement, then most subsequently relapsed (magenta lines). D. Cluster 4 patients (n = 30) showing slower response, 
and most of them had a sustained remission (green lines).
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9, adjusted OR = 0.57, 85% CI: 0.38–0.85, p = .006) and
to some extent by more prominent depressive features at
baseline (greater HAMD total score; adjusted OR = 1.10,
95% CI: 1.02–1.18, p = .013).
As we found that patients in Cluster 3 differentiated from
those in Cluster 2 by having a substantially larger number
of previous manic episodes during the preceding year, one
may question whether the study investigators considered
the baseline history of manic episodes when making a
decision to discharge a patient. From visually inspecting
the curves along with associated rates of discharge for each
cluster, it seems that the investigators tended to discharge
patents with robust improvement during the first week,
since Clusters 2 and 3 with rapid early response have the
highest proportion of early discharges. To formally evalu-
ate this relationship we fitted logistic regression models
with early discharge (yes/no as a response) and YMRS
scores during the first 7 days and various baseline and his-
torical characteristics evaluated as potential predictors.
The stepwise logistic model revealed that the most impor-
tant predictors of early discharge were baseline YMRS total
score (adjusted odds ratio (OR) = 0.89, p < .001), and
change in YMRS from baseline to evaluation at Days 2
(adjusted OR = 0.94, p = .026) and 7 (adjusted OR = 0.93,
p = .003). Interestingly, the previous number of manic
episodes had a marginally significant but positive effect
on early discharge (adjusted OR = 1.08, p = .067), which
suggests that while early discharge was driven by mania
improvement during the first 7 days, the patient's history
of recurrence of mania was not considered in making early
discharge decisions. Of course, from our data, we cannot
evaluate the possible impact on the outcome, had such
information been considered and patients with higher
number of manic episodes not been discharged.
Discussion
In this post-hoc analysis of a double-blind clinical trial [5]
in patients with bipolar mania or mixed-episode, we iden-
tified 4 clusters with different response profiles that could
be grouped into 2 contrasting sets of patterns. The first set
involved contrasting patients who rapidly improved dur-
ing the first week of treatment, some of whom either
relapsed (Cluster 3) or continued improving (Cluster 2),
and a second set contrasting patients who showed less
rapid response during the first week of treatment, one
group of which did not gain remission (Cluster 1) and the
other group continued to improve to remission (Cluster
4). The presence of psychotic features, not being in a
mixed episode and the YMRS Appearance item were the
most significant predictors of slower initial improvement
as represented by Clusters 1 and 4 vs. Clusters 2 and 3.
Patients in Clusters 1 and 4 differed in their rates of rapid
cycling at baseline, 39.1% vs. 56.7%. Interestingly Cluster
4, which had the higher rates for rapid cycling, eventually
gained remission. For Cluster 3 vs. 2, the larger number of
previous manic episodes and randomization to dival-
proex treatment were significant predictors of relapse fol-
lowing rapid reduction in symptoms. The similarity
between clinical courses for Clusters 1 and 4 and for Clus-
ters 2 and 3 during the first week of treatment and their
markedly different response profiles is interesting, and
may have implications about the importance of clinical
observation early in treatment of patients in order to avert
potential relapse.
Treatment of manic episodes may be difficult when they
are complicated by the presence of other features such as
depression, psychosis, and anxiety. Attempts have been
made to characterize subtypes of mania that may be asso-
ciated with these other features and that respond differ-
ently to treatment. In a study in untreated patients with
acute mania, Swann et al [3] utilized factor analysis of
Table 2: Baseline characteristics of patients associated with each cluster.
Cluster 1 
n = 64
Cluster 2 
n = 92
Cluster 3 
n = 36
Cluster 4 
n = 30
Age, y mean (SD) 42.8 (11.8) 40.8 (11.9) 39.7 (12.0) 40.9 (13.3)
Male, % 46.9 38.0 47.2 36.7
White Ethnicity, % 79.7 82.6 75.0 86.7
Weight, kg mean (SD) 77.8 (19.4) 81.4 (20.7) 82.7 (22.5) 75.6 (20.9)
YMRS total, mean (SD) 29.9 (6.1) 25.5 (4.6) 25.6 (4.7) 31.2 (6.7)
YMRS-09: Disruptive-aggressive behavior, mean (SD) 2.0 (1.6) 2.2 (1.5) 1.7 (1.3) 2.1 (1.5)
YMRS-10: Appearance, mean (SD)† 1.3 (1.1) 0.6 (0.9) 0.5 (0.8) 1.3 (1.0)
HAMD-21 total, mean (SD) 13.6 (7.7) 14.6 (7.6) 16.8 (5.5) 11.5 (6.2)
Mixed episode, % 28.1 58.7 58.3 13.3
Psychotic features, % 65.6 26.1 30.6 73.3
Rapid cycling, % 39.1 66.3 63.9 56.7
# manic episodes previous year, mean (SD) 2.9 (5.4) 3.9 (5.6) 8.2 (10.7) 2.9 (4.9)
Randomized to olanzapine, % 46.9 60.9 33.3 43.3BMC Psychiatry 2008, 8:65 http://www.biomedcentral.com/1471-244X/8/65
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behavioral rating scales scores followed by cluster analy-
sis, which yielded 4 mania subtypes they described as anx-
ious-depressive, psychotic, classic euphoria, and irritable.
These subtypes were subsequently found to respond dif-
ferently to treatment with divalproex or lithium [4]. The
anxious-depressed subtype had higher distressed appear-
ance scores and was resistant to treatment, the psychotic
and classic euphoria subtypes responded to either lithium
or divalproex, and the irritable subtype responded better
to divalproex than lithium.
In the current study, we used data from a clinical trial
focusing primarily on identifying patterns of response
that were based on individual mania profiles during the
active treatment and not specifically on clustering patients
by pre-treatment mania features. Therefore, the clinical
characteristics of the clusters presented herein were not as
distinct or as definitive as those for the naturalistic sub-
types described by Swann et al [3]. However, the response
profiles for the clusters in the present study are supported
by previous reports. Cluster 4, which was comprised of
more psychotic patients, with more severe mania baseline
scores, and less severe depressive scores responded to
treatment with either divalproex or olanzapine similar to
the psychotic mania subtype described by Swann et al [3].
Patients in Cluster 3, who had more severe depressive
symptoms at baseline, relapsed within 2 weeks and
remained resistant to treatment similar to the anxious-
depressed subtype [3]. In addition, Cluster 3 was charac-
terized by having more prior manic episodes, which has
been reported by Welge et al [15] to be a predictor of poor
response. Cluster 2, which responded well to treatment
with either olanzapine or divalproex, may share features
with the classic euphoria subtype of Swann et al [3]. Clus-
ter 1 characteristics and response profiles do not appear to
share similarities with any of the naturalistic mania sub-
types proposed by Swann et al [3].
Limitations
This was a post-hoc analysis of a study not designed to
assess the complexities of treatment response patterns and
warrants further study. Furthermore, replication of this
method in larger populations of patients may be needed
to validate clusters identified based on this limited data. A
further limitation is that this cluster analysis deterministi-
cally identified mania profiles ignoring the inherent
uncertainty of class membership. For example, some
patients may have had profiles on the borderline of two
response patterns. Ignoring such uncertainty may result in
overstating the odds ratios from the logistic regressions
predicting class membership. Additionally, the relation-
ships found between subscores of YMRS and class mem-
bership probabilities may be somewhat overstated
because the baseline YMRS total score was included as
part of the outcome profile creating an overlap. It is
important to emphasize that the findings of this study are
exploratory and not confirmatory; therefore interpreta-
tion of all hypothesis testing should be done with caution
and merely indicate possible existing patterns that need to
be validated in different datasets, perhaps using more
powerful clustering procedures like latent class finite mix-
ture modeling [13,16-18]. This type of modeling would
evaluate the profiles representing distinct clusters, as well
as predictors of class membership, while properly
accounting for class uncertainty within a single estimation
step. It requires certain parametric assumptions about the
curves and underlying mixture distributions, and the
results may be highly sensitive to the initial partitioning of
observations into clusters. The approach of the present
paper to cluster response profiles was exploratory and
data-driven, and is similar to that of Tarpley et al. [10,11].
In addition, our purpose was to search for interesting pat-
terns, including those that were unusual and of relatively
low occurrence potentially representing an anomaly,
which is more in line with the philosophy of exploratory
functional data analysis [14].
In an attempt to validate our exploratory findings, we
reanalyzed our data utilizing a fully parametric maxi-
mum-likelihood based approach proposed in Jones et al
[18] (that is very similar to that of Muthen and Shedden
[17]) using the freely available SAS PROC TRAJ software
[19] developed by Jones and colleagues. The clustering
structure of the data obtained using the latent class mix-
tures was very similar to our original findings, and the var-
iables identified as significant predictors of class
membership were virtually identical to those we identi-
fied using simple logistic regression. It is important to
point out, however, that the methods used in the present
analysis have not been validated in a separate study and
may have limitations that have yet to be realized.
Conclusion
Cluster analysis was useful to identify interesting patterns
in treatment response profiles that would be difficult to
detect using only pre-specified clinical definitions of
relapse or response. Patient history and features of manic
episode were important for discriminating between these
patterns. In particular, the previous number of manic epi-
sodes was found to be a risk factor for relapse in patients
who initially responded to treatment and therefore
should be considered prior to discharge.
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